Background {#Sec1}
==========

Despite intensive research efforts to better understand its tumor microenvironment, the prognosis of pancreatic cancer remains dismal \[[@CR1], [@CR2]\]. The Pancreatic Cancer Action Network estimates that deaths from pancreatic cancer will be second only to lung cancer by 2020 \[[@CR3]\]. Accordingly, novel treatment strategies for pancreatic cancer are desperately needed.

Immunotherapy is one of these novel strategies that has been under investigation in a variety of cancers. This review will focus on pancreatic cancer from an immune perspective, describing its immune microenvironment and the completed and ongoing clinical trials in this area.

Review {#Sec2}
======

Pancreatic cancer from an immune perspective {#Sec3}
--------------------------------------------

Pancreatic cancer is unique from an immunological perspective. First, intratumoral effector T-cells are rare, in contrast to many other solid tumors for which infiltration of effector T-cells is often prominent \[[@CR4], [@CR5]\]. Second, the *RAS* oncogene drives an inflammatory program that establishes immune privilege in the pancreatic tumor microenvironment (PTME) \[[@CR6]\]. Third, pancreatic cancer is associated with a massive infiltration of immunosuppressive leukocytes into the tumor microenvironment \[[@CR4], [@CR5]\]. Fourth, the development of pancreatic cancer is associated with a strong desmoplastic reaction that consists of multiple cell types, molecular factors, and extracellular matrix \[[@CR7]\]. This dense desmoplastic stromal reaction is one of the hallmarks of pancreatic cancer and plays a vital role in promoting angiogenesis while evading from immune cells \[[@CR4], [@CR8], [@CR9]\]. Studies have uncovered a rich communication between stellate cells (fibroblasts) and cancer cells \[[@CR4], [@CR8], [@CR9]\]. The abundance of PDGF (platelet derived growth factor), fibronectin, proteoglycans and hyaluronic acid distorts the normal pancreatic architecture and transforms it into a complex, abnormal configuration of seemingly impenetrable walls \[[@CR7]\]. Accordingly, this extensive stroma is not only a passive barrier for the immune system but rather interacts with cancer cells and participates in its progression and invasion \[[@CR7]\].

It is useful to examine the immune cells and receptors in pancreatic cancer based on their role in the development of an immune response and their correlation with prognosis. There are two immunological processes that determine the immune response against cancer cells: the effector process and the suppressor process. These cell types are summarized in Table [1](#Tab1){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}.Table 1Cellular Microenvironment of Pancreatic CancerCellRole in pancreatic cancerRelationship to outcomeReferenceNKdeactivated↑tumor stage and ↓survival\[[@CR11]--[@CR13]\]CD8+ T-Celldeactivated↑tumor stage and ↓survival\[[@CR5], [@CR8], [@CR13]\]CD4+ Th1-Cell↓↑tumor stage and ↓survival\[[@CR12]--[@CR14]\]TAM (M1)↓↑tumor stage\[[@CR4], [@CR12]--[@CR14]\]DCdeactivated↑survival\[[@CR8], [@CR13], [@CR17], [@CR18]\]MDSC↑↓survival\[[@CR5], [@CR12], [@CR17], [@CR25]\]Mast Cell↑↑metastases\[[@CR9], [@CR13]\]T-regs↑↓survival\[[@CR4], [@CR5], [@CR12], [@CR23], [@CR24]\]TAM (M2)↑↑stage and ↓survival\[[@CR4], [@CR12]--[@CR14]\]Fibroblast↑↑stage and ↓survival\[[@CR12], [@CR13], [@CR25], [@CR27]\]CD4 + Th2 Cell↑↑stage and ↓ survival\[[@CR5], [@CR9], [@CR12]--[@CR14], [@CR16], [@CR25]\]↑ increase, ↓ decrease, *DC* dendritic cell, *MDSC* myeloid derived suppressor cell, *NK* natural killer cell, *TAM* tumor associated macrophageFig. 1Pancreatic Cancer with Targeted Immunotherapy. DC (dendritic cell), GM-CSF (granulocyte macrophage colony stimulating factor), PD-1 (programmed cell death-1), PDL-1 (programmed cell death ligand-1), CTLA-4 (Cytotoxic T-lymphocyte associated protein-4), HSP (heat shock protein), TCR (T-cell receptor), MHC (major histocompatibility complex), vEGF-R (vascular epithelial growth factor-receptor), IDO (Indoleamine 2,3-dioxygenase), TGF (tumor growth factor), IL (interleukin), CD (cell differentiation), V (vaccine)

### Effector immune cells {#Sec4}

#### Natural killer cells (NK) {#FPar1}

An increased number of NK cells have been shown to be associated with a better prognosis in a small set of 13 patients with pancreatic cancer \[[@CR10]\], presumably due to their role in recognition and elimination of cancer cells. However, NK cells are typically found in a limited number in pancreatic cancer and often in a deactivated form due to the lack of NKG2D, a cell surface receptor found to be upregulated in activated NK cells \[[@CR11]--[@CR13]\].

#### CD8 Cytotoxic and CD4 helper T-cells or tumor infiltrating lymphocytes (TILs) {#FPar2}

The presence of TILs in pancreatic cancer has been well described and it may represent the most important element in PTME \[[@CR8], [@CR9], [@CR14], [@CR5]\]. Among these TILs, the memory (CD45RO) CD8 T-cells are thought to be the major anti-tumor effector cells and their density in resected pancreatic tumors was found to correlate with survival \[[@CR8], [@CR9]\]. On the other hand, the role of CD4 T-cells is more complex. The Th1, the effector form, activates antigen presenting cells (APC) such as dendritic cells (DCs) while the ineffective form (Th2) plays a major role in tumor tolerance \[[@CR13], [@CR5]\]. Although the presence of both CD8 and CD4 T-cells correlates with a better prognosis \[[@CR4], [@CR8], [@CR15]\], they are found in small numbers in the PTME, possibly due to effect of stroma and suppressor immune cells \[[@CR15]\]. In addition, the number of CD8 effector T-cells decreases during the malignant transformation of pre-cancer cells \[[@CR5], [@CR8]\]. Studies have shown that Th1 cells are found in disproportionately lower concentrations among pancreatic cancer cells than Th2, suggesting an ineffective immune response against tumor cells \[[@CR5], [@CR16]\].

#### Dendritic cells (DCs) {#FPar3}

The presence of DCs in the PTIM is essential in order to generate an anti-tumor immune response and, similar to TILs, is associated with a better prognosis in pancreatic cancer \[[@CR8], [@CR17], [@CR18]\]. However, DCs are present in low numbers in the PTME and often in an immature form \[[@CR8], [@CR17], [@CR18]\], thus likely limiting their ability to present foreign antigens to T-cells.

### Co-stimulatory receptors and ligands {#Sec5}

#### CD40 {#FPar4}

Is a co-stimulatory molecule that is expressed on T-cells and binds to its ligand (CD40L) on APCs, leading to the activation of lymphocytes \[[@CR13]\]. In a retrospective analysis of patients with pancreatic cancer, Unek et al., showed that the expression of CD40 in pancreatic cancer tissue samples correlates with a trend towards improved progression-free survival (PFS) and overall survival (OS) \[[@CR19]\]. Accordingly, CD40 represents a promising target in pancreatic cancer as described below.

#### OX-40 (tumor necrosis factor receptor superfamily member 4) {#FPar5}

Is a member of the TNF receptor family found on T- cells and acts as a secondary co-stimulatory molecule as it requires other co-stimulatory molecules to be expressed first prior to its activation. The expression of OX-40 is found in high concentrations on activated T-cells. In pancreatic cancer increased levels of OX-40 was reported to correlate with better survival but this data needs to be validated on a larger scale \[[@CR10]\].

#### 4-1BB (tumor necrosis factor receptor superfamily member 9) {#FPar6}

Is also a member of the TNF receptor family and found on T-cells and NK cells. Upon interaction with its ligand 4-1BBL, it promotes T cell activation, particularly CD8 lymphocyte. 4-1BB also acts as a secondary co-stimulatory molecule, similar to OX-40 \[[@CR20], [@CR21]\]. However, there is currently no data available regarding the role of 4-1BB in the PTIM.

### Suppressor immune cells {#Sec6}

#### Tumor associated macrophages (TAMs) {#FPar7}

These cells express the program cell death ligand (PD-L1) which is involved in immune suppression and T-cell apoptosis as described below. In PTIM, the presence of TAMs and it is association with poor outcomes and more frequent metastases has been well described \[[@CR4], [@CR13]\].

#### T-regulatory cells (CD4 + CD25 + FoxP3+) (T-regs) {#FPar8}

T-regs are other subsets of TILs known for their immunosuppressive activity through the release of cytokines including TGF-β and IL-10. Based on few retrospective analyses, pancreatic tumors with low numbers of T-regs were found to have a significantly better survival compared to tumors with high numbers \[[@CR4], [@CR22], [@CR23]\].

#### Myeloid derived suppressor Cell (MDSCs) {#FPar9}

In pancreatic cancer, these cells were found in pre-malignant growths and increased in concentration as cancer cells grow suggesting a direct role in immune suppression and unrestricted cancer cell growth \[[@CR5], [@CR12], [@CR16], [@CR24]\]. Interestingly, high concentration of MDSCs in the peripheral blood was associated with poor outcomes in patients with pancreatic cancer \[[@CR16]\]. Whether this correlation exists in the PTIM remains to be determined.

#### Fibroblasts/pancreatic stellate cell {#FPar10}

Fibroblasts respond to a variety of molecules including CXCL12 (C-X-C motif chemokine 12) and produce VEGF (vascular endothelial growth factor) to stimulate angiogenesis in response to hypoxia or inflammation \[[@CR7], [@CR12], [@CR13], [@CR25]\]. In pancreatic cancer, the production of VEGF by fibroblasts is associated with cancer growth and worse prognosis \[[@CR26], [@CR27]\]. Therefore, the role of fibroblasts in the PTME is currently under intense investigation.

#### Mast cells {#FPar11}

The role of mast cells in cancer has not been well-defined \[[@CR9], [@CR28], [@CR29]\]. In pancreatic cancer, it has been suggested that low concentration of mast cells in the PTME correlates with increased survival \[[@CR28]\] while increased concentration is associated with increased lymph node metastases based on retrospective analyses in small subsets of patients \[[@CR29]\].

### Co-Inhibitory Receptors and Ligands {#Sec7}

#### Program-death (PD-1) {#FPar12}

Is an inhibitory receptor that belongs to the B7-receptor family and interacts with its ligand PD-L1 (B7-H1) to down regulate signals by T-cells, leading to the induction of apoptosis in activated T-cells \[[@CR13]\]. PD-1 is expressed on progenitor T cells, activated T- and B-lymphocytes, NK cells, and myeloid cells \[[@CR13]\]. Patients with pancreatic cancer with PD-L1 positive tumors have a significantly worse prognosis than patients with PD-L1 negative tumors \[[@CR27]\]. The PD-1/PD-L1 pathway is currently one of the most targeted pathways in cancer.

#### Cytotoxic T-lymphocyte associated protein-4 (CTLA-4) {#FPar13}

Is a co-inhibitory molecule found on T- lymphocytes that deactivates these cells to induce apoptosis in response to interaction with APCs. This negative feedback loop is a key to normal immune function to prevent over-stimulation of T-cells and damage to healthy cells but is stimulated inappropriately in pancreatic cancer to create a microenvironment that promotes cancer growth rather than its recognition. CTLA-4 is overexpressed in pancreatic cancer cells and its overexpression was found to correlate negatively with survival in patients who underwent surgical resection \[[@CR30]\].

#### CXCL12 (C-X-C motif chemokine ligand 12) {#FPar14}

Is a chemokine that is found in high concentration in pancreatic cancer and is involved in fibroblast migration and proliferation. The increased concentration of CXCL12 in the cancer microenvironment creates a network of dense stroma restricting immune cells migration and recognition of cancer antigens. Feig et al., showed that the inhibition of this chemokine resulted in increased T-cell infiltration into pancreatic cancer in murine models \[[@CR27]\].

#### T-cell immunoglobulin and mucin-domain containing molecule 3 (TIM-3) {#FPar15}

Is a transmembrane protein that is involved in the regulation of Th1 lymphocytes. The interaction between TIM-3 and CD4 Th1 cells has been studied in pancreatic cancer patients and found to correlate with tumor vascular invasion \[[@CR31]\]. However, the role of TIM-3 needs to be further characterized in pancreatic cancer and other malignancies.

#### Soluble lymphocyte activation gene-3 (LAG-3) {#FPar16}

Is an important T-cell regulator that interacts with MHC class II molecules expressed on APCs. This interaction promotes activation and maturation of DCs but negatively regulates effector T-cells. LAG-3 has been shown to be necessary for T-regulatory cell activity and represents a novel target for therapy in pancreatic cancer \[[@CR32]\].

#### Indoleamine 2,3-dioxygenase (IDO) {#FPar17}

Is an enzyme involved in cleaving tryptophan into kynurenine. Tryptophan is required for T-cell activation and kynurenine leads to T-regs differentiation and chemotaxis \[[@CR33]\]. Increased levels of IDO, as seen in pancreatic cancer, creates a microenvironment devoid of effector T-cells but rich in immunosuppressive T-regs \[[@CR34]\]. IDO inhibitors are currently under investigation in pancreatic cancer and other malignancies (NCT02048709 and NCT02077881).

#### Galectins (Gal-1, Gal-3 and Gal-9) {#FPar18}

Are immune modulating glycoproteins that are overexpressed in pancreatic cancer cells and thought to be involved in T-cell homeostasis. These glycoproteins have been shown to promote immune suppression in pancreatic cancer by promoting Th2 and T-reg transformation, restricting DC maturation and stimulating stellate cells \[[@CR35], [@CR36]\]. Their association with survival in pancreatic cancer has been conflicting, with several studies showing increased concentration associated with decreased survival \[[@CR37], [@CR38]\], while others showed an association with improved outcomes \[[@CR39]\].

#### B7-H3 {#FPar19}

Is a member of the B7 ligand family that can be induced in activated dendritic cells, monocytes, and T cells leading to decrease Th1 type response and cytokine production. B7-H3 expression was found to correlate with lymph node metastases and advanced pathologic stage in patients with pancreatic cancer \[[@CR40]\]. The inhibition of B7-H3 increased CD8+ TILs and inhibited tumor growth in mice \[[@CR40]\].

Pancreatic cancer vaccines {#Sec8}
--------------------------

Cancer vaccines aim to stimulate the immune system against tumor cells by generating humoral and/or cellular immune responses. Many forms of cancer vaccines exist but generally they can be divided into synthetic and cellular-based vaccines.

### Synthetic vaccines (summarized in Table [2](#Tab2){ref-type="table"}) {#Sec9}

Table 2Completed immunotherapy clinical trialsTreatment typeTarget*N*Additional therapyCancer stageImmunologic responseClinical outcomeRefPeptide vaccinesCEA23NoneResected or Metastatic↑ IFN-γ T cell response by ELISPOT with increasing vaccine dose37 % survival at 32 months\[[@CR77]\]CEA + MUC120NoneMetastaticNRmOS of 7.3 ms\[[@CR78]\]Gastrin 17154NoneMetastatic74 % + ELISA↑OS by 54 % vs placebo (*p* = 0.03)\[[@CR51]\]Gastrin 17383NoneMetastaticCorrelation between anti-gastrin17 titers and OSNo benefit\[[@CR53]\]Gastrin 1730NoneMetastatic67 % + ELISA↑OS (4 to 7.2 ms if + IR (*p* \< 0.01)\[[@CR52]\]GVAX + Mesothelin90CyclophosphamideMetastaticNR↑OS (4 to 6.2 ms)\[[@CR63]\]Hedgehog59GemcitabineMetastaticNRmOS 10 ms\[[@CR79]\]KRAS23NoneResected85 % + DTH10 year OS of 20 %\[[@CR56]\]KRAS48GM-CSFResected(10) and Metastatic (38)58 % + DTH↑OS (2 to 5.4 ms if + IR (*p* = 0.0002)\[[@CR54]\]KRAS24GM-CSFResected11 % + DTHmOS 20.3 ms\[[@CR55]\]KRAS39GemcitabineResected47 % + ELISpot↑OS by 21.7 wks if + IR (*p* \< 0.01)\[[@CR57]\]MUC116SB-AS adjuvantResected31 % + DHTNo benefit\[[@CR42]\]MUC16Incomplete Freund\'sMetastatic17 % + ELISANo benefit\[[@CR41]\]Telomerase1062GemcitabineMetastaticNRNo benefit\[[@CR47]\]Telomerase520GemcitabineMetastaticNRNo benefit\[[@CR48]\]Telomerase48GM-CSFMetastatic63 % + DHTmOS of 4.3 ms if + IR (*p* \< 0.01)\[[@CR50]\]Telomerase178GemcitabineMetastaticNRNo benefit\[[@CR49]\]Trop-27NoneMetastaticNRNo benefit\[[@CR80]\]VEGF607Erlotinib + GemcitabineMetastaticNRNo benefit\[[@CR44]\]VEGF535GemcitabineUnresectableNRNo benefit alone\[[@CR46]\]VEGF150GemcitabineUnresectableNRNo benefit\[[@CR46]\]Wilm\'s Tumor gene-132GemcitabineUnresectable58 % + DTH↑mOS by 7 ms if DHT + (*p* \< 0.01)\[[@CR81]\]Autologous: DCMUC-149GemcitabineMetastatic↓65 % T-regs2 CR, 5 PR ,10 SD\[[@CR59]\]MUC117NoneResected and UnresectableNRmOS of 9 ms\[[@CR82]\]MUC-120noneMetastaticCorrelation between CD38+ cells and OS1 pt had remission of lung mets, 5 had stable disease. mOS 9.8 mos\[[@CR58]\]MUC-110NoneResectedNo difference30 % OS 4 years\[[@CR83]\]MUC-12NoneMetastatic↑117 % CD8+ MUC-1 specific cellsNo benefit\[[@CR84]\]Wilm\'s Tumor gene-110GemcitabineMetastatic57 % + DTH↑OS if + DTH\[[@CR85]\]AllogeneicGM-CSF605-FUResected↑ mesothelin + ELISPOT↑OS (53 % to 76 % if + IR)\[[@CR61]\]GM-CSF14Adjuvant CRTResected21 % + DTHDFS of 25 ms if + R\[[@CR60]\]GM-CSF30CyclophosphamideMetastatic↑Mesothelin ELISPOTNo benefit\[[@CR62]\]Adoptive cell transferMesothelin6NoneMetastaticNR33 % with stable disease\[[@CR65]\]MUC128NoneResected (20) and Unresectable (8)↑10 % effector T-cells , ↓5.7 % TregsmOS 5 ms in unresectable,\
19 % 3 year OS in resectable\[[@CR64]\]MUC120NoneUnresected↑CD8+ T-cellsmOS 9.8 ms,\
1 year OS 20 %\[[@CR58]\]Immune checkpoint inhibitorCD4021GemcitabineUnresected (7) and Metastatic (20)N/A↑mOS by 1.7 ms vs gemcitabine alone, 1 patient had complete resolution of hepatic metasteses\[[@CR68]\]CTLA-430GVAXUnresectable or metastaticN/A↑1 year OS by 20 % compared to GVAX alone\[[@CR75]\]CTLA-427noneUnresected (7) and Metastatic (20)N/A1 patient delayed regression of hepatic metasteses\[[@CR70]\]PD-L114noneMetastaticN/ANo benefit\[[@CR69]\]↑ increase, ↓ decrease, *CR* complete response, *CRT* chemoradiation, *CTLA-4* Cytotoxic T-lymphocyte associated protein-4, *DC* dendritic cell, *DTH* delayed typed hypersensitivity, *GM-CSF* granulocyte macrophage colony stimulating factor, *MDSC* myeloid derived suppressor cell, *mOS* median overall survival, *Ms* months, *N/A* not applicable, *NK* natural killer cell, *NR* not reported, *OS* overall survival, *PD-L1*, programmed cell death ligand-1, *PR* partial response, *R* response, *SD* stable disease, *TAM* tumor associated macrophages, *Wk* weeks

Synthetic vaccines are typically made from whole protein or peptides that match a pre-determined antigen to induce a T- cell response. Despite multiple large trials targeting MUC1 \[[@CR41]--[@CR43]\], VEGF \[[@CR44]--[@CR46]\], telomerase \[[@CR47]--[@CR50]\] and gastrin-17 \[[@CR51]--[@CR53]\], none have shown a meaningful survival benefit. These trials, however, were able to show significant immune responses to the targeted antigens. Some trials using mutated RAS peptide vaccine alone \[[@CR54]--[@CR56]\] or in combination with gemcitabine \[[@CR57]\] have shown clinical benefit. Importantly, this benefit was mainly seen in patients who demonstrated positive immune responses \[[@CR54], [@CR56], [@CR57]\].

### Cellular-based vaccines (summarized in Table [2](#Tab2){ref-type="table"}) {#Sec10}

Cellular-based vaccines use cancer cells (either whole cells or cell lysates) as the source of the antigens, allowing the immune system to utilize multiple antigens rather than a single epitope. Overall the results of these trials are encouraging; however, each included a small number of patients making it difficult for meaningful interpretation. Cellular based vaccines can be divided into autologous or allogeneic vaccines based on the source of the cells.

#### Autologous vaccines {#FPar20}

In this process, the patient's own dendritic cells are isolated and pulsed with a specific antigen before being re-infused back to the patient. Multiple studies have used this vaccination approach targeting variety of antigens. MUC1 is one of the most targeted antigens given its overexpression in pancreatic cancer and its association with tumor invasion and metastasis. The clinical outcome of this vaccination method was not impressive; however, an interesting correlation with immune biomarkers was identified such as increased CD38 (a marker for activated lymphocytes) \[[@CR58]\] and decreased T-regs \[[@CR59]\].

#### Allogeneic vaccine {#FPar21}

In this method of vaccination, a pancreatic cancer cell line is stimulated, usually with GM-CSF, in order to elicit an immune response when administered to patients with pancreatic cancer. A group at John Hopkins used this form of cancer vaccine (GVAX) in combination with 5-FU or chemoradiation in the adjuvant setting and showed an increase in PFS and OS in patients who developed an immune response against mesothelin \[[@CR60], [@CR61]\]. The same group also investigated GVAX in the metastatic setting in combination with low dose cyclophosphamide, to deplete T-regs, demonstrating an increase in mesothelin specific T-cell response with no survival benefit \[[@CR62]\]. More recently, GVAX was combined with a Listeria vaccine that expresses mesothelin in 90 patients with metastatic disease. The combination of these 2 vaccines showed an improved OS compared to the allogeneic vaccine alone (6.1 vs 3.9 months, *p* = 0.01). Interestingly, patients who derived the most benefit of this combination were patients who received over 3 doses of the vaccine (9.7 vs 4.6 months, *p* = 0.01) and patients who received at least 2 previous chemotherapy regimens (5.1 vs 3.7 months, *p* = 0.001) \[[@CR63]\]. This combination has currently a breakthrough designation by FDA while being investigated in patients with metastatic disease in a large ongoing clinical trial.

Adoptive T- cell transfer (summarized in Table [2](#Tab2){ref-type="table"}) {#Sec11}
----------------------------------------------------------------------------

In this approach the patient's T-cells are expanded and activated *ex vivo* then re-infused back to the patient. Based on the source and the method used for T-cell activation, adoptive T- cell transfer could be classified into: Tumor infiltrating lymphocytes (TILs), engineered T- cells that express a specific cancer T-cell receptor (TCR), and T- cells that express a chimeric antigen receptor (CAR). This methodology of immunotherapy had gained a lot of attention recently due to promising clinical outcomes in hematological malignancies. However, the efficacy of adoptive T- cell transfer remains to be determined in solid tumors including pancreatic cancer. Kawaoka et al., investigated MUC1-specific cytotoxic T lymphocytes (CTLs) in 28 patients and showed 19 % 3-year survival in patients with resectable disease along with increased effector lymphocytes and decreased T-regs \[[@CR64]\]. More recently, the University of Pennsylvania group presented their experience using autologous T- cells modified with a chimeric antigen receptor (CAR) that recognizes mesothelin in pancreatic cancer patients with refractory metastatic disease. Of the 6 patients treated 2 had stable disease with one patient had a decreased PET avidity of hepatic metastases. Overall, the treatment was well tolerated \[[@CR65]\]. The carcinoembryonic antigen (CEA) is another attractive target in pancreatic cancer that is currently been explored in clinical trials (NCT01723306, NCT00004178 and NCT01212887). New generations of CAR therapies are under investigation with a focus on increasing their activities and specificities and decreasing their toxicities. The CAR T-cells efficacy could be enhanced by engineering the intracellular domain to contain co-stimulatory molecules such as 41BB and OX40 or combining CAR T-cells therapy with immune modulators such as cyclophosphamide in order to deplete T-regulatory cells (NCT02465983) or immune checkpoint inhibitors such as CTLA-4 and anti-PD1 antibodies.

Immune checkpoint inhibitors and co-stimulatory agonists (summarized in Table [2](#Tab2){ref-type="table"}) {#Sec12}
-----------------------------------------------------------------------------------------------------------

Immune checkpoint inhibitors represent a paradigm shift in cancer treatment due to their promising clinical activities in melanoma and other malignancies \[[@CR66], [@CR67]\]. However, a limited number of studies targeting these immune checkpoints have been completed in pancreatic cancer. The first study to investigate the co-stimulatory agonists in pancreatic cancer used CD40 agonist in combination with gemcitabine in 21 patients with locally advanced or metastatic disease. This study demonstrated promising outcomes with an improvement of median OS compared to gemcitabine alone and one patient having a complete resolution of his liver metastases \[[@CR68]\]. In the area of immune checkpoint inhibitors, both CTLA-4 and PD-L1 inhibitors were investigated in patients with locally advanced or metastatic pancreatic cancer in 2 clinical trials. The clinical outcomes were disappointing, although, only small number of patients were treated on both trials \[[@CR69], [@CR70]\]. To date, the only immune checkpoint inhibitor to show activity in pancreatic cancer is MEDI4736 (anti-PD-L1), which showed a PR rate of 8 % in a preliminary analysis of this going trial \[[@CR71]\]. While this suggests a response can be achieved with single immunotherapy, it remains dismal and maybe improved by combination therapy. This approach is currently being investigated in few ongoing trials as detailed in Table [3](#Tab3){ref-type="table"}.Table 3On-going immunotherapy clinical trialsTreatment typePhaseTarget*N*Additional therapyStageIdentifierChimeric antibodyI,IIEnsituximab116NoneMetastaticNCT01040000^a^DNA vaccineIVEGFR-272NoneMetastaticNCT01486329^a^Fungal vector vaccineIIRAS176GemcitabineResectedNCT00300950^a^Viral vector vaccineISmall Pox Virus36NoneMetastaticNCT00574977^a^Allogeneic vaccineICEA48GM-CSFMetastaticNCT00028496^a^IDonor Lymphocyte37NoneMetastaticNCT00161187^a^IDendritic cells12Poly-ICLCUnresectableNCT01677962IIGM-CSF60Cetuximab + CyclophosphamideMetastaticNCT00305760^a^IIGVAX56NoneMetastaticNCT00389610IIGVAX87CyclophosphamideResectableNCT0072744IIGVAX19Cyclophosphamide, Radiation, FOLFIRINOXResectedNCT01595321IIGVAX +/- Mesothelin93CyclophosphamideMetastaticNCT01417000IIGVAX +/- Mesothelin240Gemcitabine, Capecitabine, 5-FU, Irinotecan, Erlotinib or CyclophosphamideMetastaticNCT02004262IIIFN-α + GM-CSF14CyclophosphamideMetastaticNCT00002773^a^IIIVirulizin400Gemcitabine +/- 5-FUMetastaticNCT00040092^a^Autologous vaccineICEA24NoneMetastaticNCT00004604^a^ICEA14NoneMetastaticNCT00027534^a^ICEA24Denileukin DiftitoxMetastaticNCT00128622^a^IICEA48IL-2MetastaticNCT01723306IDendritic Cells2Gemcitabine + Stereotactic RadiosurgeryMetastaticNCT00547144^a^IIKLH35RadiationMetastaticNCT00868114ImmunotherapyIB7-H393noneAllNCT01391143ICD4010Gemcitabine + nab-paclitaxelMetastaticNCT02588443ICD4010GemcitabineresectedNCT01456585^a^IICTLA-482NoneMetastaticNCT00112580^a^ICTLA-437GemcitabineMetastaticNCT00556023^a^ICTLA-428GemcitabineMetastaticNCT01473940IICTLA-4 + GVAX92FOLFIRINOXMetastaticNCT01896869IIIDO98Gemcitabine + nab-paclitaxelmetastaticNCT02077881IIL-1-Ra13FOLFIRINOXMetastaticNCT02021422I/IIPD-156Capecitabine + RadiationResectable and Borderline ResectableNCT02305186IPD-L11038noneAllNCT01693562Peptide vaccineI,IIAlpha (1, 3) galactosyltransferase7NoneMetastaticNCT00255827^a^IIIAlpha (1, 3) galactosyltransferase280FOLFIRINOXLocally AdvancedNCT01836432IIIAlpha (1,3) galactosyltransferase722Gemcitabine, 5-FU, radiationResectedNCT01072981I,IICEA28NoneMetastaticNCT00529984^a^ICEA + MUC118NoneUnresectableNCT00669734IhCG-β36NoneMetastaticNCT00648102^a^IhCG-β48NoneMetastaticNCT00709462^a^IHeat Shock Protein16NoneResectedNCT00003025^a^I/IIHedgehog122GemcitabineMetastaticNCT01130142^a^IHedgehog21FOLFIRINOXUnresectableNCT01383538IMUC125NoneResected or Locally AdvancedNCT00008099^a^I/IIMUC5AC90Gemcitabine + nab-paclitaxelUnresectableNCT01834235IP5312NoneUnresectableNCT01191684^a^IIP53 + RAS70IL-2MetastaticNCT00019084^a^IRAS7NoneMetastaticNCT00006387^a^IRAS33NoneMetastaticNCT00019006^a^IIITelomerase1110Capecitabine + GemcitabineMetastaticNCT00425360^a^ITGF-β168GemcitabineResectable and unresectableNCT01373164ITrophoblast glycoprotein44NoneMetastaticNCT00056537^a^I/IIVEGF17GemcitabineUnresectableNCT00655785^a^IVEGFR-221GemcitabineMetastaticNCT00622622^a^*5-FU* 5-flurouracil, *CEA* Carcinoembryonic antigen, *CTLA-4* Cytotoxic T-lymphocyte associated protein-4, *FOLFIRINOX* folinic acid, fluorouracil, irinotecan, oxaliplatin, *GM-CSF* granulocyte macrophage colony stimulating factor, *hCG* Human chorionic gonadotropin, *IDO* indoleamine 2,3-dioxygenase, *IFN* interferon, *IL-2* interleukin-2, *KLH* keyhole limpet hemocyanin, *MUC* mucin, *N* number, *PD* programmed death, *PD-L* programmed death ligand, *Poly-ICLC* carboxymethylcellulose, polyinosinic-polycytidylic acid, and poly-L-lysine double-stranded RNA, *TGF* Transforming growth factor, *VEGF* Vascular endothelial growth factor, *VEGF-R* Vascular endothelial growth factor receptor^a^Study listed as complete but results not published

Combination therapy {#Sec13}
-------------------

Due to the lack of meaningful clinical benefits of cancer vaccines, the potential positive immunological effect of chemotherapy and radiation therapy, and the promising outcomes of immune checkpoint inhibitors, the focus has shifted towards combining these modalities. Gemcitabine, a standard chemotherapy that is used traditionally to treat pancreatic cancer, has been found to mediate immunological effects such as tumor associated antigen cross presentation by dendritic cells and the induction and expansion of cytotoxic T cells responses in addition to reduce the number of myeloid suppressor cells \[[@CR72], [@CR73]\]. Radiation therapy can also increase the immunogenic properties of tumor cells by enhancing MHC class I expression, thereby increasing their vulnerability to CTLs. Another frequent effect of DNA damage inflicted by radiotherapy or chemotherapy is the increase in the expression of death receptors (in particular Fas/CD95 and TNF-related apoptosis-inducing ligand \[TRAIL\] receptors, enabling lysis of the tumor cells by Fas/CD95 ligand and TRAIL-positive immune effectors \[[@CR74]\]. As detailed in Table [3](#Tab3){ref-type="table"}, the majority of ongoing trials investigate a combination strategy of the immunotherapy with chemotherapy, radiation or both. Of interest are multiple trials targeting mesothelin and/or GVAX with chemoradiation and multiple immune checkpoint inhibitors combined with chemotherapy. Our group is currently investigating the immunological effect of the combination of chemoradiation and anti-PD-1 as a neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer compared to neoadjuvant chemoradiation alone (NCT02305186). This neoadjuvant setting will allow investigators to study the effect of combination therapy on the tumor microenvironment. Another promising combination by the Hopkins group combined GVAX with anti-CTLA-4 and demonstrated a 1-year improvement in OS by 20 % compared to GVAX and cyclophosphamide alone \[[@CR75]\].

Conclusion {#Sec14}
==========

Despite the ongoing efforts outlined in this review, the prognosis of pancreatic cancer remains dismal. With the recent progress in cancer immunotherapy, there are glimmers of hope in new immune targets with more being identified each year. These advancements are moving from the bench to the bedside at a rapid pace, with the hope of translating into improvements in clinical outcomes. We believe that immunotherapy represents a promising modality in pancreatic cancer. However, there still remains much to be learned about the pancreatic immune microenvironment and its role in the immune escape of cancer cells. In order to develop an active strategy to enhance the immune response against pancreatic cancer that could be translated to a promising clinical outcome we must focus our efforts on increasing the density of the intratumoral effector T-cells; decreasing or inhibiting the immunosuppressive cells and receptors; and understanding the role of the stromal reaction and its interaction with pancreatic cancer immune microenvironment. Indeed, the recent encouraging data of patients with mismatch-repair deficient colorectal cancer responding to pembrolizumab requires further investigation, particularly as it may be relevant for a small number of patients with pancreatic cancer \[[@CR76]\]. Improved response rates and survival benefits may be achieved by using combination therapies; identifying novel biomarkers in order to select the group of patients who may drive the most benefit of cancer immunotherapy; and implementing novel clinical trials designs that allow for tumor samples collection in order to understand the mechanism of action and resistance of pancreatic cancer to immunotherapy.
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4-1BB

:   Tumor Necrosis Factor Receptor Superfamily Member 9

APC

:   antigen presenting cell

CD

:   cell differentiation

CR

:   complete response

CRT

:   chemoradiation

CTLA-4

:   Cytotoxic T-lymphocyte associated protein-4

CXCL12

:   C-X-C motif chemokine 12

DC

:   dendritic cell

DTH

:   delayed typed hypersensitivity

ELISA

:   enzyme linked immunosorbent assay

FOLFIRINOX

:   folinic acid, fluorouracil, irinotecan, oxaliplatin

Gal

:   Galectins

GM-CSF

:   granulocyte macrophage colony stimulating factor

HSP

:   heat shock protein

IDO

:   Indoleamine 2,3-dioxygenase

IFN-γ

:   interferon-gamma

IL

:   interleukin

LAG-3

:   Soluble Lymphocyte Activation Gene-3

MDSC

:   myeloid derived suppressor cell

MHC

:   major histocompatibility complex

mOS

:   median overall survival

ms

:   months

NA

:   not applicable

NK

:   natural killer cell

NR

:   not reported

OS

:   overall survival

OX-40

:   Tumor Necrosis Factor Receptor Superfamily Member 4

PD-1

:   programmed cell death-1

PDGF

:   platelet derived growth factor

PD-L1

:   programmed cell death-ligand 1

PR

:   partial response

PTME

:   pancreatic tumor microenvironment

R

:   response

SD

:   stable disease

TAM

:   tumor associated macrophages

TCR

:   T-cell receptor

TGF

:   tumor growth factor

TIL

:   tumor infiltrating lymphocyte

TIM-3

:   T-cell Immunoglobulin and mucin-domain containing molecule 3

vEGF

:   vascular epithelial growth factor

vEGF-R

:   vascular epithelial growth factor-receptor

**Competing interests**

Paul Kunk has no conflicts of interest to disclose.

Osama Rahma is supported in part by a research grant from Investigatory-Initiated Studies Program of Merck, Sharp & Dohme Corp.

Todd Bauer is has equity ownership of iTi Health, Inc. and is a consultant for Hemoshear, LLC.

Craig Slingluff receives funding from NIH but not related to the topic of this review.

**Authors' contributions**

PK collected the data and drafted the manuscript. OR revised the manuscript. TB and CS provided additional revisions for the manuscript. All authors read and approved the final manuscript.

**Authors' information**

PK is currently an Oncology Fellow at the University of Virginia (UVA) with interest in gastrointestinal malignancy. Awarded the Farrow Oncology Fellowship Award, he is currently studying the immune profile of cholangiocarcinoma and is gaining expertise in the field of hepatobiliary cancer and immunotherapy. OR is an Assistant Professor in the Division of Hematology/Oncology at UVA. During his previous training at the National Cancer Institute, he was involved in conducting cancer vaccine clinical trials and the development of immune checkpoint inhibitors. As a member of the Emily Couric Cancer Center and in collaboration with other investigators, his main focus is to study hepatobiliary cancers and to identify potential targets and immune biomarkers that may correlate with outcomes. He is currently a Principal Investigator on many immunotherapy clinical trials in GI cancers and is the lead physician of the GI Oncology team. TB is an Associate Professor of Surgery in the Division of Surgical Oncology, with emphasis on hepatobiliary tumors. Receipt of several awards for clinical and research excellence, his research focus is the immune relationship to pancreatic cancer and early detection of pancreatic cancer. He is the director of the High-Risk Pancreatic Cancer Clinic and a Principal Investigator in many clinical trials in GI cancers. CS is a Professor of Surgery in the Division of Surgical Oncology and a leading expert in the immune profile and immunotherapy of melanoma. He is a Principal Investigator in several clinical trials in melanoma.

No additional acknowledgements other than those listed as authors. There were no sources of funding for this review.
